Proof of Usefulness Report

RNAimmune

Analysis completed on 2/17/2026

+465
Proof of Usefulness Score
Industry Mainstay

RNAimmune is a verifiable biotechnology company and subsidiary of Sirnaomics, specializing in mRNA-based therapeutics and vaccines with approximately $37M in funding (Series A). They have achieved significant regulatory milestones, including FDA IND clearance for Phase I clinical trials of their RSV and COVID-19 booster vaccines. However, the submission's claim that 'most people have used my product' is demonstrably false, as the products are still in early clinical stages with no commercial availability. The project scores high on technical innovation and potential utility but low on current audience reach and response integrity.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+85
Audience Reach Impact+10
Technical Innovation+90
Evidence Of Traction+45
Market Timing Relevance+75
Functional Completeness+10
Subtotal+50.375
Usefulness Multiplierx0.92
Final Score+463

Project Details

Project URL
Description
At RNAimmune, we use mRNA technology to help people live full and healthy lives. Our primary focus is development of vaccines against cancer and respiratory viruses. Our expertise in design and production of mRNA vaccines is supported by research and development efforts toward novel lipids, targeted delivery and antigen engineering. We collaborate with the world for the health of everyone.

Algorithm Insights

Market Position
Strong market validation with clear user adoption patterns
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline